Leading pharmaceutical company in Tunisia, the Company of Pharmaceutical Industries of Tunisia, SIPHAT, till loses money.
After posting a net loss of 3.7 million dinars in 2016, the company has announced a deficit of 5 million in the first half of this year.
According to the financial statements closed on June 30, SIPHAT posted revenues of 16.9 million dinars against 19.7 million dinars the same date a year earlier, down 14.5% due mainly to the decline in hospital sales (-12%).
As for operating expenses, they have almost stagnated (-2%) compared to the end of June 2016 to reach 20.9 million dinars.
Therefore, the operating result for the period is negative by 4 million dinars compared with – 1.6 million a year earlier.